Global phase 2 data in TNBC look similar to earlier results in China.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
It’s less about being fast, more about producing a better product.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
